EGFR and non-small cell lung carcinoma: Given these properties, 1G and 2G EGFR-TKIs for several years have represented the standard of care (SOC) first-line treatment for advanced EGFRM+NSCLC, with the choice of first-line between 1G and 2G mostly linked to different toxicity profiles and mutation types, as afatinib is associated with more frequent side effects and is more effective in NSCLC cases harboring exon 19dels and uncommon EGFR-mutations than in patients with L858R [13,14].